Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Neoplasms 2Myeloproliferative Disorders 2Hodgkin Disease 2GATA2 Deficiency 2Anemia, Refractory, with Excess of Blasts 2Pathologic Complete Response 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 18Specimen Handling 17Magnetic Resonance Spectroscopy 12Biopsy 12Paclitaxel 9Carboplatin 8Radiosurgery 7Nivolumab 7trastuzumab deruxtecan 6Pemetrexed 6Leucovorin 6Irinotecan 6Fulvestrant 6Fluorouracil 6Bevacizumab 6palbociclib 5Oxaliplatin 5Letrozole 5Gemcitabine 5Cetuximab 5Taxes 4Cisplatin 4Capecitabine 4olaparib 3enzalutamide 3durvalumab 3Ipilimumab 3Docetaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Azacitidine × 30 days × Clear all
NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡